BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38396378)

  • 1. Risk stratification of LA-NPC during chemoradiotherapy based on clinical classification and TVRR.
    Tang Q; Mei C; Huang B; Huang R; Kang L; Chen A; Lei N; Deng P; Ying S; Zhang P; Qin Y
    Cancer Med; 2024 Feb; 13(3):e7029. PubMed ID: 38396378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
    Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
    Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
    Shen H; Yin J; Niu R; Lian Y; Huang Y; Tu C; Liu D; Wang X; Lan X; Yuan X; Zhang J
    Radiother Oncol; 2022 Jun; 171():107-113. PubMed ID: 35461950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.
    Yang H; Liu Y; Zhang R; Ye Y; Chen Q; Qin Q; Huang L; Li X; Cai R; Tang H; Jiang W
    Oral Oncol; 2020 Nov; 110():104897. PubMed ID: 32679404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
    Chen J; Liu T; Sun Q; Jin T
    Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus DNA change level combined with tumor volume reduction ratio after inductive chemotherapy as a better prognostic predictor in locally advanced nasopharyngeal carcinoma.
    Xiang ZZ; He T; Zeng YY; Liu F; Shao BF; Yang T; Ma JC; Wang XR; Yu ST; Liu L
    Cancer Med; 2023 Jan; 12(2):1102-1113. PubMed ID: 35852473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of adjuvant chemotherapy on survival in patients with residual nasopharyngeal carcinoma after undergoing concurrent chemoradiotherapy.
    Yang S; Lin S; Fu Q; Cai B; Kong F; Huang G; Li F; Wang H
    PLoS One; 2015; 10(3):e0120019. PubMed ID: 25799566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
    Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
    Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
    Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
    Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
    Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
    Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
    Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
    Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma.
    Liao K; Tao HY; Zhan ZJ; Qiu WZ; Zheng RH
    Oncol Res Treat; 2021; 44(11):602-612. PubMed ID: 34601467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant or Adjuvant Chemotherapy Plus Concurrent CRT Versus Concurrent CRT Alone in the Treatment of Nasopharyngeal Carcinoma: A Study Based on EBV DNA.
    Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Li Y; Tang QN; Sun XS; Liang YJ; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
    J Natl Compr Canc Netw; 2019 Jun; 17(6):703-710. PubMed ID: 31200353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.
    Xu C; Chen YP; Liu X; Li WF; Chen L; Mao YP; Zhang Y; Guo R; Zhou GQ; Tang LL; Lin AH; Sun Y; Ma J
    Oral Oncol; 2017 Jun; 69():99-107. PubMed ID: 28559028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy.
    Topkan E; Yucel Ekici N; Ozdemir Y; Besen AA; Mertsoylu H; Sezer A; Selek U
    Ear Nose Throat J; 2021 Feb; 100(2):NP69-NP76. PubMed ID: 31184210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.